Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 165

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 165
---
 the world would be prohibitively expensive, and its intellectual property rights in some countries outside the United States and Switzerland can be less extensive than those in the United States and Switzerland. In addition, the laws of some foreign countries do not protect intellectual property to the same extent as laws in the United States and Switzerland. Consequently, NLS may not be able to seek to prevent third parties from practicing its inventions in all countries outside the United States and Switzerland, or from selling or importing products made using its inventions in and into the United States or other jurisdictions. Competitors, for example, may use its technologies in jurisdictions where NLS has not obtained patents to develop their own products and further, may export otherwise infringing products to territories where NLS has patents, but enforcement is not as strong as that in the United States and Switzerland. Many companies have encountered significant problems in protecting and defending intellectual property in foreign jurisdictions. The legal systems of certain countries, particularly China and certain other developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to medical devices and biopharmaceutical and biotechnology products, which could make it difficult for it to stop the infringement of its patents or marketing of competing products in violation of its proprietary rights generally. To date, NLS has not 47 sought to enforce any issued patents in these foreign jurisdictions. Proceedings to enforce its patent rights in foreign jurisdictions could result in substantial costs and divert its efforts and attention from other aspects of its business, could put its patents at risk of being invalidated or interpreted narrowly and its patent applications at risk of not issuing and could provoke third parties to assert claims against us. NLS may not prevail in any lawsuits that NLS initiates and the damages or other remedies awarded, if any, may not be commercially meaningful. The requirements for patentability may differ in certain countries, particularly developing countries. Certain countries in Europe and developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, NLS and its licensors may have limited remedies if patents are infringed or if NLS or its licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit its potential revenue opportunities. Accordingly, its efforts to enforce its intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that NLS develops or licenses. If NLS is unable to maintain effective proprietary rights for its product candidates